The cytotoxic efficacy of CD8+ T cells take an upper hand after the 1st and 2nd dose of T11TS, indicating significant lymphocyte proliferation and activation but most significant increase in the cell count of CD8+ T cells and hence improvement in the cytotoxic activity of the lymphocytes (CD8+ T cells), is observed after the administration of the 3rd dose of T11TS (Fig 9), which actually helps in eliminating malignant glioma cells. The gene discussed is CD8A; the disease is malignant glioma.